Escolar Documentos
Profissional Documentos
Cultura Documentos
FATO RELEVANTE
Na presente data, a Rede d1000 foi informada que o Conselho de Administração da Profarma,
sua controladora, aprovou uma proposta de investimento em ações de sua emissão, por meio
de operações no mercado de bolsa a serem realizadas no ambiente da B3 S.A. - Brasil, Bolsa,
Balcão, em até 1 (um) ano a contar da data deste Fato Relevante, limitado à quantidade total
de até 4.500.000 ações DMVF3, cabendo à Diretoria da Profarma a definição de se, quando e
em quais termos tais aquisições serão feitas.
MATERIAL FACT
Profarma Distribuidora de Produtos Farmacêuticos S.A. – B3: PFRM3 (“Profarma”) and d1000
Varejo Farma Participações S.A. – B3: DMVF3 (“Rede d1000” and, when jointly with Profarma,
“Companies”), hereby inform their respective shareholders and the market in general of the
following:
On the present date, Rede d1000 was informed that the Board of Directors of Profarma, its
parent company, approved an investment proposal in shares issued by it, through stock
market operations to be carried out in the environment of B3 SA - Brasil, Exchange, Over-the-
counter, within 1 (one) year from the date of this Material Fact, limited to the total amount of
up to 4,500,000 DMVF3 shares, and Profarma's Board of Executive Officers is responsible for
defining whether, when and under what terms such acquisitions will be made.
The Companies inform that the potential investment will observe the legislation and
regulations in force, especially regarding the sending, by the Companies, of the information
required by arts. 11 and 12 of the Securities and Exchange Commission Resolution No. 44, of
August 23, 2021, and by the Novo Mercado Regulation.
The Companies will keep their respective shareholders informed of any updates to the
investment proposal, and the Investor Relations Department of both Companies remains
available to their shareholders to clarify any questions related to the object of this Material
Fact through (i) the telephone (21) 4009-0200, from the website https://ri.profarma.com.br
and from the e-mail address ri@profarma.com.br, to Profarma; and (ii) from the telephone
number (21) 4009-0200, from the website https://ri.d1000varejofarma.com.br and from the
e-mail address ri@d1000varejofarma.com.br, to the Rede d1000.